AN ASSESSMENT OF POTENTIAL DRUG-DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS IN A TERTIARY CARE HOSPITAL

KAMESWARAN R.; PRAVEEN M.; KRISHNAVENI KANDASAMY; SAMBATHKUMAR R.

doi:10.22159/ijpps.2019v11i3.30801

Authors

KAMESWARAN R. J. K. K. Nattraja College of Pharmacy, Kumarapalayam 638183, Tamil Nadu, India,
PRAVEEN M. Departmentof Pharmacy Practice,J. K. K. Nattraja College of Pharmacy, Kumarapalayam 638183, Tamil Nadu, India
KRISHNAVENI KANDASAMY J. K. K. Nattraja College of Pharmacy, Kumarapalayam 638183, Tamil Nadu, India
SAMBATHKUMAR R. Department of Pharmaceutics, J. K. K. Nattraja College of Pharmacy, Kumarapalayam 638183, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ijpps.2019v11i3.30801

Keywords:

Hypertensive patients, PDDIs, Aspirin and clopidogrel, Incidences, Pharmacodynamics

Abstract

Objective: To an assessment of potential drug-drug interactions in hypertensive patients in a tertiary care hospital.

Methods: A prospective, observational study was conducted at a tertiary care hospital, Erode for a period of 8 mo. A sample of 480 patients was assessed for PDDIs using drug checker in Micromedex^®-2.7.

Results: A total of 430 patients were analyzed and it was found to be 396 (82.50%) hypertensive patients had PDDIs, and a sum total of 1160 PDDIs were observed. Potential drug-drug interactions (PDDIs) higher in female hypertensive patients [255 (64.39%)] compared to males. Incidences of PDDIs were found to be higher in the age group of 60-70 y were [177 (44.69%)] and incidences of interactions based on the duration of (4-6 d) hospital stays were 272 (68.68%). Moreover, 49.24% of patients were found to be prescribed with more than 7 drugs, with higher incidences of PDDIs. Some of the most common drug interacting pair was between aspirin and clopidogrel combination observed in 325 PDDIs in the major, with pharmacodynamics in nature.

Conclusion: Clinical pharmacist ought to have the role of regular monitoring of drug therapy in identifying and preventing the medications that have the potential to cause drug-drug interactions, thereby minimizing the undesirable outcomes in drug medical care and improving the quality of care.

Downloads

Download data is not yet available.

References

A global brief on hypertension: silent killer, global public health crisis. WHO/DCO/WHD/2013.2. Available from: http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/. [Last accessed 11 Aug 2016]

Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The framingham heart study. Circulation 1997;96:308-15.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. National heart, lung, and blood institute; national high blood pressure education program coordinating committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.

Causes of Death. Geneva, World Health Organization; 2008. Available from: http://www.who.int/health info/global-burdendisease/cod2008sourcesmethods.pdf. [Last accessed 14 Jul 2016].

Lim SS, Vos T. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010:a systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2224-60.

World Health Organization. Global status report on non-communicable diseases 2010. Geneva, World Health Organization; 2011.

World Health Organization. Global Health Observatory Data Repository. Geneva, World Health Organization; 2008. Available from: http://apps.who.int/go/data/view.main. [Last accessed 11 Feb 2013]

Munger MA. Polypharmacy and combination therapy in the management of hypertension in elderly patients with co-morbid diabetes mellitus. Drugs Aging 2010;27:871-83.

Ginsberg G, Hattis D, Russ A, Sonawane B. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ Health Perspect 2005;113:1243-9.

Cooney D, Pascuzzi K. Polypharmacy in the elderly: focus on drug interactions and adherence in hypertension. Clin Geriatr Med 2009;25:222-33.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. Task force members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 2013;31:1281-57.

Atika Wahyu Puspitasari, Azizahwati Azizahwati, Ayu Rahmawati Hidayat. Analysis of potential drugs interaction on antihypertension drugs prescription in community health center of the sukmajaya district in a period of June-November 2015. Asian J Pharm Clin Res 2017;10:61-5.

Kameswaran R, Krishnaveni Kandasamy, Shanmugaampathkumar Sundaram. The incidence of potential drug-drug interactions in cardiac patients in a tertiary care hospital. Int J Recent Sci Res 2018;9:27271-4.

Rakesh Romday, Ajay Kumar Gupta, Pawan Bhambani. An assessment of antihypertensive drug prescription patterns and adherence to joint national committee-8 hypertension treatment guidelines among hypertensive patients attending a tertiary care teaching hospital. Int J Res Med Sci 2016;4:5125-33.

Nitin Kothari, Barna Ganguly. Potential drug-drug interactions among medications prescribed to hypertensive patients. J Clin Diagn Res 2014;8:1-4.

Greeshma K George, Siraj Sundaran, Ashar Ali Cp, Mubeena Km, Thansiya Ph, Babu G, et al. Study of drug-drug interaction in the inpatients of a tertiary care hospital at calicut. Asian J Pharm Clin Res 2018;11:162-4.

Santi Purna Sari, Afi Fauziyah Darajat, Binar Nursanti. Drug interactions among patients with hypertension taking angiotensin-converting enzyme inhibitors in an Indonesian hospital. Int J Appl Pharm 2018;10:138-1.